The U.S. Food and Drug Administration (FDA) has approved ZYCUBO® (Copper Histidinate) developed by Sentynl Therapeutics as the first and currently the only drug for the treatment of the rare pediatric disease Menkes disease. Clinical data supporting this approval show that patients who received early treatment had nearly an 80% reduction in risk of death, with a median overall survival of 177.1 months, compared to only 17.6 months in the untreated control group.